Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Aug;72(2):483–492. doi: 10.1172/JCI110996

Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

P E Daddona, B S Mitchell, H J Meuwissen, B L Davidson, J M Wilson, C A Koller
PMCID: PMC1129206  PMID: 6603477

Abstract

In most instances, marked deficiency of the purine catabolic enzyme adenosine deaminase results in lymphopenia and severe combined immunodeficiency disease. Over a 2-yr period, we studied a white male child with markedly deficient erythrocyte and lymphocyte adenosine deaminase activity and normal immune function. We have documented that (a) adenosine deaminase activity and immunoreactive protein are undetectable in erythrocytes, 0.9% of normal in lymphocytes, 4% in cultured lymphoblasts, and 14% in skin fibroblasts; (b) plasma adenosine and deoxyadenosine levels are undetectable and deoxy ATP levels are only slightly elevated in lymphocytes and in erythrocytes; (c) no defect in deoxyadenosine metabolism is present in the proband's cultured lymphoblasts; (d) lymphoblast adenosine deaminase has normal enzyme kinetics, absolute specific activity, S20,w, pH optimum, and heat stability; and (e) the proband's adenosine deaminase exhibits a normal apparent subunit molecular weight but an abnormal isoelectric pH. In contrast to the three other adenosine deaminase-deficient healthy subjects who have been described, the proband is unique in demonstrating an acidic, heat-stable protein mutation of the enzyme that is associated with less than 1% lymphocyte adenosine deaminase activity. Residual adenosine deaminase activity in tissues other than lymphocytes may suffice to metabolize the otherwise lymphotoxic enzyme substrate(s) and account for the preservation of normal immune function.

Full text

PDF
486

Images in this article

487FIGURE 1
on p.487
487FIGURE 2
on p.487
488FIGURE 3
on p.488

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carson D. A., Kaye J., Matsumoto S., Seegmiller J. E., Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A. 1979 May;76(5):2430–2433. doi: 10.1073/pnas.76.5.2430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carson D. A., Kaye J., Wasson D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol. 1981 Jan;126(1):348–352. [PubMed] [Google Scholar]
  3. Chen S. H., Scott C. R., Swedberg D. R. Heterogeneity for adenosine deaminase deficiency: Expression of the enzyme in cultured skin fibroblasts and amniotic fluid cells. Am J Hum Genet. 1975 Jan;27(1):46–52. [PMC free article] [PubMed] [Google Scholar]
  4. Cohen A., Hirschhorn R., Horowitz S. D., Rubinstein A., Polmar S. H., Hong R., Martin D. W., Jr Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):472–476. doi: 10.1073/pnas.75.1.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coleman M. S., Donofrio J., Hutton J. J., Hahn L., Daoud A., Lampkin B., Dyminski J. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem. 1978 Mar 10;253(5):1619–1626. [PubMed] [Google Scholar]
  6. Daddona P. E., Frohman M. A., Kelley W. N. Human adenosine deaminase and its binding protein in normal and adenosine deaminase-deficient fibroblast cell strains. J Biol Chem. 1980 Jun 25;255(12):5681–5687. [PubMed] [Google Scholar]
  7. Daddona P. E., Frohman M. A., Kelley W. N. Radioimmunochemical quantitation of human adenosine deaminase. J Clin Invest. 1979 Sep;64(3):798–803. doi: 10.1172/JCI109526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Daddona P. E. Human adenosine deaminase. Properties and turnover in cultured T and B lymphoblasts. J Biol Chem. 1981 Dec 10;256(23):12496–12501. [PubMed] [Google Scholar]
  9. Daddona P. E., Kelley W. N. Analysis of normal and mutant forms of human adenosine deaminase - a review. Mol Cell Biochem. 1980 Feb 8;29(2):91–101. doi: 10.1007/BF00220303. [DOI] [PubMed] [Google Scholar]
  10. Daddona P. E., Kelley W. N. Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts. Biochim Biophys Acta. 1981 Apr 14;658(2):280–290. doi: 10.1016/0005-2744(81)90298-9. [DOI] [PubMed] [Google Scholar]
  11. Daddona P. E., Kelley W. N. Human adenosine deaminase. Purification and subunit structure. J Biol Chem. 1977 Jan 10;252(1):110–115. [PubMed] [Google Scholar]
  12. Daddona P. E., Kelley W. N. Human adenosine deaminase. Stoichiometry of the adenosine deaminase-binding protein complex. Biochim Biophys Acta. 1979 Oct 24;580(2):302–311. doi: 10.1016/0005-2795(79)90143-0. [DOI] [PubMed] [Google Scholar]
  13. Donofrio J., Coleman M. S., Hutton J. J., Daoud A., Lampkin B., Dyminski J. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest. 1978 Oct;62(4):884–887. doi: 10.1172/JCI109201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  15. Hirschhorn R., Beratis N., Rosen F. S. Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme. Proc Natl Acad Sci U S A. 1976 Jan;73(1):213–217. doi: 10.1073/pnas.73.1.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hirschhorn R. Conversion of human erythrocyte-adenosine deaminase activity to different tissue-specific isozymes. Evidence for a common catalytic unit. J Clin Invest. 1975 Mar;55(3):661–667. doi: 10.1172/JCI107974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hirschhorn R., Roegner V., Jenkins T., Seaman C., Piomelli S., Borkowsky W. Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest. 1979 Oct;64(4):1130–1139. doi: 10.1172/JCI109552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hopkinson D. A., Harris H. The investigation of reactive sulphydryls in enzymes and their variants by starch gel electrophoresis. Studies on red cell adenosine deaminase. Ann Hum Genet. 1969 Jul;33(1):81–87. doi: 10.1111/j.1469-1809.1969.tb01632.x. [DOI] [PubMed] [Google Scholar]
  19. Jenkins T., Rabson A. R., Nurse G. T., Lane A. B. Deficiency of adenosine deaminase not associated with severe combined immunodeficiency. J Pediatr. 1976 Nov;89(5):732–736. doi: 10.1016/s0022-3476(76)80792-5. [DOI] [PubMed] [Google Scholar]
  20. Jenkins T. Red-blood-cell adenosine deaminase deficiency in a "healthy" Kung individual. Lancet. 1973 Sep 29;2(7831):736–736. doi: 10.1016/s0140-6736(73)92568-3. [DOI] [PubMed] [Google Scholar]
  21. Koller C. A., Stetson P. L., Nichamin L. D., Mitchell B. S. An assay of deoxyadenosine and adenosine in human plasma by HPLC. Biochem Med. 1980 Oct;24(2):179–184. doi: 10.1016/0006-2944(80)90009-5. [DOI] [PubMed] [Google Scholar]
  22. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  23. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  24. MARTIN R. G., AMES B. N. A method for determining the sedimentation behavior of enzymes: application to protein mixtures. J Biol Chem. 1961 May;236:1372–1379. [PubMed] [Google Scholar]
  25. Martin D. W., Jr, Gelfand E. W. Biochemistry of diseases of immunodevelopment. Annu Rev Biochem. 1981;50:845–877. doi: 10.1146/annurev.bi.50.070181.004213. [DOI] [PubMed] [Google Scholar]
  26. Mitchell B. S., Kelley W. N. Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann Intern Med. 1980 Jun;92(6):826–831. doi: 10.7326/0003-4819-92-6-826. [DOI] [PubMed] [Google Scholar]
  27. Mitchell B. S., Mejias E., Daddona P. E., Kelley W. N. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5011–5014. doi: 10.1073/pnas.75.10.5011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Polmar S. H. Metabolic aspects of immunodeficiency disease. Semin Hematol. 1980 Jan;17(1):30–43. [PubMed] [Google Scholar]
  29. Schrader W. P., Stacy A. R. Immunoassay of the adenosine deaminase complexing proteins of human tissues and body fluids. J Biol Chem. 1979 Dec 10;254(23):11958–11963. [PubMed] [Google Scholar]
  30. Schrader W. P., Stacy A. R., Pollara B. Purification of human erythrocyte adenosine deaminase by affinity column chromatography. J Biol Chem. 1976 Jul 10;251(13):4026–4032. [PubMed] [Google Scholar]
  31. Siaw M. F., Mitchell B. S., Koller C. A., Coleman M. S., Hutton J. J. ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6157–6161. doi: 10.1073/pnas.77.10.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Swallow D. M., Evans L., Hopkinson D. A. Several of the adenosine deaminase isozymes are glycoproteins. Nature. 1977 Sep 15;269(5625):261–262. doi: 10.1038/269261a0. [DOI] [PubMed] [Google Scholar]
  33. Thompson L. F., Seegmiller J. E. Adenosine deaminase deficiency and severe combined immunodeficiency disease. Adv Enzymol Relat Areas Mol Biol. 1980;51:167–210. doi: 10.1002/9780470122969.ch4. [DOI] [PubMed] [Google Scholar]
  34. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wiginton D. A., Hutton J. J. Immunoreactive protein in adenosine deaminase deficient human lymphoblast cell lines. J Biol Chem. 1982 Mar 25;257(6):3211–3217. [PubMed] [Google Scholar]
  36. Wortmann R. L., Mitchell B. S., Edwards N. L., Fox I. H. Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A. 1979 May;76(5):2434–2437. doi: 10.1073/pnas.76.5.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES